imatinib mesylate has been researched along with Hypophosphatemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ernst, D; Fischman, A; Florenzano, P; Guarda, FJ; Ivanovic-Zuvic, D; Jiménez, M; Martínez, A; Toro, L | 1 |
| Han, SB; Jung, WK; Kim, SJ; Lee, SH; Park, SW; Park, SY; Yang, KH | 1 |
| Amet, Y; Berthou, C; Dalbies, F; Eveillard, JR; Grall, P; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Berman, E; Chanel, S; Fleisher, M; Heller, G; Maki, RG; Nicolaides, M; Sauter, NP; Scheu, K; Wilson, BA | 1 |
| Hatfield, A; Letvak, L; Owen, S | 1 |
| Joensuu, H; Reichardt, P | 1 |
| Lyritis, GP; Tournis, S | 1 |
| Durán, A; Noblejas, AG; Osorio, S; Steegmann, JL | 1 |
| Browett, P; Grey, A; O'Sullivan, S; Reid, IR | 1 |
| Coppo, P; Fouqueray, B; François, H; Hayman, JP; Mougenot, B; Ronco, P | 1 |
| Egorin, MJ; Flick, SM; Fu, P; Gibbons, J; Grem, JL; Ivy, SP; Lagattuta, TF; Lenz, HJ; LoRusso, PA; Mani, S; Mulkerin, DL; Murgo, AJ; Parise, RA; Pavlick, A; Ramanathan, RK; Remick, SC; Reynolds, S; Shibata, S; Takimoto, CH; Wang, Y | 1 |
2 trial(s) available for imatinib mesylate and Hypophosphatemia
| Article | Year |
|---|---|
Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Remodeling; Fanconi Syndrome; Female; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Imatinib Mesylate; Kidney Tubules, Proximal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Biological; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Renal Aminoacidurias | 2012 |
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Biological Availability; Creatinine; Female; Half-Life; Humans; Hypophosphatemia; Imatinib Mesylate; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Neoplasms; Piperazines; Pyrimidines | 2008 |
9 other study(ies) available for imatinib mesylate and Hypophosphatemia
| Article | Year |
|---|---|
[Hypophosphatemia induced by carboxymaltose iron and imatinib. Report of two cases].
Topics: Administration, Intravenous; Adult; Female; Fibroblast Growth Factor-23; Humans; Hypophosphatemia; Imatinib Mesylate; Iron; Male; Middle Aged; Phosphates | 2020 |
Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Bone and Bones; Bone Remodeling; Female; Femoral Fractures; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines; Radiography | 2010 |
Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Topics: Benzamides; Biomarkers; Bone and Bones; Bone Remodeling; Calcitriol; Calcium; Female; Gastrointestinal Stromal Tumors; Humans; Hypophosphatemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Phosphates; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Vitamin D | 2006 |
Imatinib and altered bone and mineral metabolism.
Topics: Benzamides; Biomarkers; Bone and Bones; Humans; Hypophosphatemia; Imatinib Mesylate; Phosphates; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Imatinib and altered bone and mineral metabolism.
Topics: Benzamides; Calcium; Chemotherapy, Adjuvant; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Hypophosphatemia; Imatinib Mesylate; Phosphates; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Imatinib and altered bone and mineral metabolism.
Topics: Benzamides; Biomarkers; Blood Specimen Collection; Bone and Bones; Calcium; Humans; Hypophosphatemia; Imatinib Mesylate; Osteocalcin; Parathyroid Hormone; Phosphates; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Vitamin D | 2006 |
Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
Topics: Adolescent; Adult; Aged; Benzamides; Calcium; Cohort Studies; Female; Humans; Hypophosphatemia; Imatinib Mesylate; Interferon-alpha; Kidney Tubules; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Parathyroid Hormone; Phosphates; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2007 |
Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.
Topics: Adult; Benzamides; Biomarkers; Bone Remodeling; Calcium; Female; Fusion Proteins, bcr-abl; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Pyrimidines | 2006 |
Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
Topics: Antineoplastic Agents; Benzamides; Fanconi Syndrome; Female; Humans; Hypophosphatemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Phosphates; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |